ProQR Therapeutics (PRQR) Convertible Debt (2013)
ProQR Therapeutics (PRQR) posted quarterly Convertible Debt of $3.6 million for Q4 2013.
ProQR Therapeutics (PRQR) Convertible Debt (2013) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Convertible Debt for 1 consecutive years, with $3.6 million the latest figure, recorded in Q4 2013.
- Quarterly Convertible Debt changed N/A year-over-year to $3.6 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $3.6 million (changed N/A YoY) and the FY2013 annual result came in at $3.6 million, changed N/A from the prior year.
- Convertible Debt steadied at $3.6 million in Q4 2013 per PRQR's latest filing.
- Over the last five years, Convertible Debt for PRQR reached as high as $3.6 million in Q4 2013 and fell as low as $3.6 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 3.63 Mn |